PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
PacBio (PACB) reported Q4 2024 financial results with revenue of $39.2 million, marking a 33% decrease from $58.4 million in the prior year. The quarter saw instrument revenue of $15.3 million, including 23 Revio® and 7 Vega™ systems, while consumables revenue remained flat at $18.8 million.
The company reported a GAAP net income of $3.6 million ($0.01 per share), compared to a loss of $82.0 million in Q4 2023, primarily due to a $154.4 million gain from debt restructuring. Non-GAAP net loss was $55.3 million. Cash position stood at $389.9 million, down from $631.4 million year-over-year.
Notable developments included the early launch of the Vega sequencing platform, implementation of SPRQ chemistry enabling sub-$500 genome sequencing, and a debt restructuring that reduced convertible notes by $259 million.
PacBio (PACB) ha riportato i risultati finanziari del quarto trimestre 2024, con un fatturato di 39,2 milioni di dollari, segnando una diminuzione del 33% rispetto ai 58,4 milioni di dollari dell'anno precedente. Nel trimestre, il fatturato degli strumenti è stato di 15,3 milioni di dollari, includendo 23 sistemi Revio® e 7 sistemi Vega™, mentre il fatturato dei consumabili è rimasto stabile a 18,8 milioni di dollari.
L'azienda ha riportato un utile netto GAAP di 3,6 milioni di dollari (0,01 dollari per azione), rispetto a una perdita di 82,0 milioni di dollari nel quarto trimestre 2023, principalmente a causa di un guadagno di 154,4 milioni di dollari dalla ristrutturazione del debito. La perdita netta non-GAAP è stata di 55,3 milioni di dollari. La posizione di cassa si è attestata a 389,9 milioni di dollari, in calo rispetto ai 631,4 milioni di dollari dell'anno precedente.
Sviluppi significativi hanno incluso il lancio anticipato della piattaforma di sequenziamento Vega, l'implementazione della chimica SPRQ che consente il sequenziamento del genoma a meno di 500 dollari e una ristrutturazione del debito che ha ridotto le note convertibili di 259 milioni di dollari.
PacBio (PACB) informó los resultados financieros del cuarto trimestre de 2024, con ingresos de 39,2 millones de dólares, lo que representa una disminución del 33% en comparación con los 58,4 millones de dólares del año anterior. En el trimestre, los ingresos por instrumentos fueron de 15,3 millones de dólares, incluyendo 23 sistemas Revio® y 7 sistemas Vega™, mientras que los ingresos por consumibles se mantuvieron estables en 18,8 millones de dólares.
La compañía reportó una ganancia neta GAAP de 3,6 millones de dólares (0,01 dólares por acción), en comparación con una pérdida de 82,0 millones de dólares en el cuarto trimestre de 2023, principalmente debido a una ganancia de 154,4 millones de dólares por la reestructuración de la deuda. La pérdida neta no-GAAP fue de 55,3 millones de dólares. La posición de efectivo se situó en 389,9 millones de dólares, por debajo de los 631,4 millones de dólares del año anterior.
Los desarrollos notables incluyeron el lanzamiento anticipado de la plataforma de secuenciación Vega, la implementación de la química SPRQ que permite la secuenciación del genoma por menos de 500 dólares y una reestructuración de la deuda que redujo las notas convertibles en 259 millones de dólares.
PacBio (PACB)는 2024년 4분기 재무 결과를 보고했으며, 수익은 3,920만 달러로 전년 5,840만 달러에 비해 33% 감소했습니다. 이번 분기에는 기기 수익이 1,530만 달러였으며, 여기에는 23개의 Revio® 시스템과 7개의 Vega™ 시스템이 포함되었고, 소모품 수익은 1,880만 달러로 변동이 없었습니다.
회사는 GAAP 순이익이 360만 달러(주당 0.01달러)라고 보고했으며, 이는 2023년 4분기에 8,200만 달러의 손실에 비해 개선된 수치로, 주로 1억 5,440만 달러의 부채 재구성으로 인한 이익 덕분입니다. 비GAAP 순손실은 5,530만 달러였습니다. 현금 보유액은 3억 8,990만 달러로, 전년 동기 6억 3,140만 달러에서 감소했습니다.
주요 발전 사항으로는 Vega 시퀀싱 플랫폼의 조기 출시, 500달러 이하의 유전체 시퀀싱을 가능하게 하는 SPRQ 화학물질의 구현, 그리고 2억 5,900만 달러의 전환사채를 감소시킨 부채 재구성이 포함되었습니다.
PacBio (PACB) a annoncé les résultats financiers du quatrième trimestre 2024, avec des revenus de 39,2 millions de dollars, marquant une diminution de 33 % par rapport à 58,4 millions de dollars l'année précédente. Au cours du trimestre, les revenus des instruments se sont élevés à 15,3 millions de dollars, comprenant 23 systèmes Revio® et 7 systèmes Vega™, tandis que les revenus des consommables sont restés stables à 18,8 millions de dollars.
L'entreprise a déclaré un revenu net GAAP de 3,6 millions de dollars (0,01 dollar par action), contre une perte de 82,0 millions de dollars au quatrième trimestre 2023, principalement en raison d'un gain de 154,4 millions de dollars provenant de la restructuration de la dette. La perte nette non-GAAP s'élevait à 55,3 millions de dollars. La position de trésorerie était de 389,9 millions de dollars, en baisse par rapport à 631,4 millions de dollars d'une année sur l'autre.
Les développements notables comprenaient le lancement anticipé de la plateforme de séquençage Vega, la mise en œuvre de la chimie SPRQ permettant le séquençage du génome à moins de 500 dollars, et une restructuration de la dette qui a réduit les billets convertibles de 259 millions de dollars.
PacBio (PACB) hat die finanziellen Ergebnisse für das vierte Quartal 2024 bekannt gegeben, mit Einnahmen von 39,2 Millionen Dollar, was einem Rückgang von 33% im Vergleich zu 58,4 Millionen Dollar im Vorjahr entspricht. Im Quartal betrugen die Einnahmen aus Geräten 15,3 Millionen Dollar, einschließlich 23 Revio®- und 7 Vega™-Systemen, während die Einnahmen aus Verbrauchsmaterialien stabil bei 18,8 Millionen Dollar blieben.
Das Unternehmen berichtete von einem GAAP-Nettoeinkommen von 3,6 Millionen Dollar (0,01 Dollar pro Aktie), verglichen mit einem Verlust von 82,0 Millionen Dollar im vierten Quartal 2023, hauptsächlich aufgrund eines Gewinns von 154,4 Millionen Dollar aus der Umstrukturierung von Schulden. Der Nettoverlust nach GAAP betrug 55,3 Millionen Dollar. Die Barposition belief sich auf 389,9 Millionen Dollar, ein Rückgang von 631,4 Millionen Dollar im Jahresvergleich.
Zu den bemerkenswerten Entwicklungen gehörten der vorzeitige Start der Vega-Sequenzierungsplattform, die Implementierung der SPRQ-Chemie zur Ermöglichung von Genomsequenzierungen unter 500 Dollar und eine Schuldenumstrukturierung, die die wandelbaren Anleihen um 259 Millionen Dollar reduzierte.
- GAAP gross margin improved to 26% from 16% YoY
- Non-GAAP operating expenses decreased to $68.6M from $88.4M YoY
- Successful debt restructuring reduced convertible notes by $259M
- Early launch of Vega sequencing platform
- Introduction of SPRQ chemistry enabling sub-$500 genome sequencing
- Revenue declined 33% YoY to $39.2M
- Instrument revenue decreased 56% YoY to $15.3M
- Cash position decreased to $389.9M from $631.4M YoY
- $90.1M non-cash impairment charges for goodwill and R&D
- Non-GAAP net loss of $55.3M
Insights
PacBio's Q4 2024 results paint a complex picture of a company in transition. The 33% revenue decline to
The debt restructuring, which reduced outstanding convertible notes by
Two key developments could drive future growth:
- The SPRQ chemistry launch enables sub-
$500 HiFi long-read human genome sequencing while reducing DNA input requirements by75% , potentially expanding the addressable market significantly. - The Berry Genomics collaboration opens opportunities in the Chinese clinical market, particularly in prenatal and newborn screening.
However, the declining cash position (
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024.
Fourth quarter results
- Revenue of
$39.2 million , a33% decrease compared with$58.4 million in the prior-year period. - Instrument revenue of
$15.3 million compared with$35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems. - Consumables revenue of
$18.8 million compared with$18.9 million in the prior-year period. - Service and other revenue of
$5.1 million compared with$4.4 million in the prior-year period.
Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.
GAAP gross margin of
GAAP operating expenses totaled
Operating expenses, net income, and basic net income per share for the quarter ended December 31, 2024 include the impact of estimated preliminary non-cash impairment charges of approximately
GAAP net income for the fourth quarter of 2024 was
Cash, cash equivalents, and investments, excluding restricted cash, at December 31, 2024, totaled
Highlights since PacBio's last earnings release
- Accelerated Launch of Vega: Commenced shipments of Vega, our benchtop sequencing platform, ahead of schedule—expanding access to HiFi long-read sequencing for a broader range of customers.
- Clinical Collaboration with Berry Genomics: Delivered the first Vega systems as part of an early access agreement, supporting targeted assay development for prenatal health, carrier screening, and newborn screening programs in China and other markets. Additionally, Berry plans to obtain NMPA approval for its thalassemia carrier screening assay on existing PacBio technology.
- Breakthrough in Cost and Efficiency with SPRQ Chemistry: Commenced shipment of SPRQ chemistry, enabling sub-
$500 HiFi long-read human genome sequencing while reducing DNA input requirements by75% , driving increased sample throughput and helped drive Revio instrument placements at new customers in the fourth quarter. - Strengthened Financial Position: Executed the convertible note exchange, reducing the outstanding principal balance of the convertible notes by
$259 million by replacing$459 million in1.5% convertible notes due 2028 with$200 million in new1.5% convertible notes due August 2029, 20.5 million shares of common stock and$50 million in cash. - Scientific Leadership in Genetic Disease Research:
- Radboud University Medical Center Study: Used Revio to identify
93% of pathogenic variants in samples that had been difficult to detect and required multiple testing modalities. - University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and complex Mendelian condition.
- Radboud University Medical Center Study: Used Revio to identify
- Leadership Appointments:
- Appointed David Ruggiero as Head of Global Sales and Service, bringing deep experience in sales leadership across technology and life sciences, including Zoom Video Communications, Microsoft Corporation, and Thermo Fisher Scientific.
- Added Chris Smith, Chief Executive Officer of NeoGenomics, Inc., to the Board of Directors, leveraging his expertise in genomics, diagnostics, and corporate strategy to support PacBio’s growth initiatives.
"2024 was a challenging yet transformative year for PacBio, marked by the successful launch of new products, disciplined cost management, and strategic progress in our clinical strategy. Despite macroeconomic pressures, we have continued to innovate and expand accessibility to HiFi sequencing,” said Christian Henry, President and CEO of PacBio. "Looking ahead to 2025, while the macro environment remains uncertain, I believe PacBio can return to growth and expand market share as the Vega benchtop platform and SPRQ chemistry enable more researchers, clinical labs, and smaller institutions to harness the power of HiFi sequencing."
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its fourth quarter ended December 31, 2024 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1-888-349-0136 if outside the U.S., by dialing 1-412-317-0459, requesting to join the “PacBio Q4 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Statement regarding use of non‐GAAP financial measures
PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison.
PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release, such as impairment charges, merger-related expenses, changes in fair value of contingent consideration, loss on extinguishment of debt, gain on debt restructuring, amortization of acquired intangible assets, income tax benefits, restructuring costs and other adjustments and rounding differences. The amortization of acquired intangible assets excluded from GAAP financial measures relates to acquired intangible assets. The amortization related to these intangible assets will occur in future periods until they are fully amortized. Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors.
PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release.
Statement regarding preliminary financial results
This press release contains preliminary financial results which are unaudited and based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies; expectations with respect to commercialization, development and shipment of PacBio products; PacBio’s financial guidance and expectations for future periods; the amounts of the preliminary estimated non-cash impairment charges; and developments affecting our industry and the markets in which we compete, including the impact of new products and technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of U.S. export restrictions on the shipment of PacBio products to certain countries; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; other risks associated with general macroeconomic conditions and geopolitical instability; additional sustained declines in PacBio’s stock price and further changes in the timing of expected future cash flows; and adjustments arising in connection with the preparation and audit of PacBio’s financial statements as of and for the year ended December 31, 2024 resulting in changes to the amounts of the preliminary estimated non-cash impairment charges and other preliminary financial results presented in this press release. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Annual Report on Form 10-K when filed with the Securities and Exchange Commission.
Contacts
Investors:
Todd Friedman
ir@pacb.com
Media:
pr@pacb.com
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Statements of Operations | |||||||||||
| Three Months Ended | |||||||||||
| (in thousands, except per share amounts) | December 31, 2024 | September 30, 2024 | December 31, 2023 | ||||||||
| Revenue: | |||||||||||
| Product revenue | $ | 34,098 | $ | 35,296 | $ | 54,001 | |||||
| Service and other revenue | 5,126 | 4,671 | 4,356 | ||||||||
| Total revenue | 39,224 | 39,967 | 58,357 | ||||||||
| Cost of Revenue: | |||||||||||
| Cost of product revenue (1) | 23,476 | 23,278 | 40,421 | ||||||||
| Cost of service and other revenue | 3,469 | 3,484 | 3,496 | ||||||||
| Amortization of acquired intangible assets | 2,221 | 3,201 | 1,433 | ||||||||
| Loss on purchase commitment | — | — | 3,436 | ||||||||
| Total cost of revenue | 29,166 | 29,963 | 48,786 | ||||||||
| Gross profit | 10,058 | 10,004 | 9,571 | ||||||||
| Operating Expense: | |||||||||||
| Research and development | 27,466 | 25,516 | 44,544 | ||||||||
| Sales, general and administrative (2) | 41,641 | 43,746 | 45,996 | ||||||||
| Impairment charges (3) | 90,100 | — | — | ||||||||
| Merger-related expenses (4) | — | — | 63 | ||||||||
| Change in fair value of contingent consideration (5) | (1,950 | ) | 1,170 | 1,100 | |||||||
| Amortization of acquired intangible assets | 4,629 | 3,649 | 5,416 | ||||||||
| Total operating expense | 161,886 | 74,081 | 97,119 | ||||||||
| Operating loss | (151,828 | ) | (64,077 | ) | (87,548 | ) | |||||
| Gain on debt restructuring (6) | 154,407 | — | — | ||||||||
| Interest expense | (2,757 | ) | (3,538 | ) | (3,571 | ) | |||||
| Other income, net | 4,065 | 6,890 | 8,383 | ||||||||
| Income (loss) before income taxes | 3,887 | (60,725 | ) | (82,736 | ) | ||||||
| Income tax provision (benefit) (7) | 316 | — | (718 | ) | |||||||
| Net income (loss) | 3,571 | (60,725 | ) | (82,018 | ) | ||||||
| Net income (loss) per share: | |||||||||||
| Basic | $ | 0.01 | $ | (0.22 | ) | $ | (0.31 | ) | |||
| Diluted | $ | (0.49 | ) | $ | (0.22 | ) | $ | (0.31 | ) | ||
| Weighted average shares outstanding used in calculating net income (loss) per share | |||||||||||
| Basic | 282,999 | 272,915 | 267,121 | ||||||||
| Diluted | 306,892 | 272,915 | 267,121 | ||||||||
| (1) | Balance for the three months ended September 30, 2024 includes restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. |
| (2) | Balances for the three months ended December 31, 2024 and September 30, 2024 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. |
| (3) | Preliminary estimated goodwill and in-process research and development impairment charges during the three months ended December 31, 2024 driven primarily by macroeconomic factors which have impacted our cash flow projections, among other factors. |
| (4) | Merger-related expenses for the three months ended December 31, 2023 consisted of transaction costs arising from the acquisition of Apton. |
| (5) | Change in fair value of contingent consideration during the three months ended December 31, 2024, September 30, 2024, and December 31, 2023 was due to fair value adjustments of milestone payments payable upon the achievement of the respective milestone event. |
| (6) | Gain on debt restructuring during the three months ended December 31, 2024, represents the gain resulting from the November 2024 convertible notes exchange transaction. |
| (7) | Deferred income tax benefits during the three months ended December 31, 2023 are related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. |
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Statements of Operations | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| (in thousands, except per share amounts) | 2024 | 2023 | 2024 | 2023 | |||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 34,098 | $ | 54,001 | $ | 136,149 | $ | 183,872 | |||||||
| Service and other revenue | 5,126 | 4,356 | 17,865 | 16,649 | |||||||||||
| Total revenue | 39,224 | 58,357 | 154,014 | 200,521 | |||||||||||
| Cost of Revenue: | |||||||||||||||
| Cost of product revenue(1) | 23,476 | 40,421 | 92,284 | 127,568 | |||||||||||
| Cost of service and other revenue(1) | 3,469 | 3,496 | 14,057 | 14,754 | |||||||||||
| Amortization of acquired intangible assets | 2,221 | 1,433 | 9,393 | 1,983 | |||||||||||
| Loss on purchase commitment | — | 3,436 | 998 | 3,436 | |||||||||||
| Total cost of revenue | 29,166 | 48,786 | 116,732 | 147,741 | |||||||||||
| Gross profit | 10,058 | 9,571 | 37,282 | 52,780 | |||||||||||
| Operating Expense: | |||||||||||||||
| Research and development(1) | 27,466 | 44,544 | 134,922 | 187,170 | |||||||||||
| Sales, general and administrative(2) | 41,641 | 45,996 | 175,017 | 169,818 | |||||||||||
| Impairment charges(3) | 90,100 | — | 183,300 | — | |||||||||||
| Merger-related expenses(4) | — | 63 | — | 9,042 | |||||||||||
| Change in fair value of contingent consideration(5) | (1,950 | ) | 1,100 | (850 | ) | 15,060 | |||||||||
| Amortization of acquired intangible assets | 4,629 | 5,416 | 18,006 | 6,157 | |||||||||||
| Total operating expense | 161,886 | 97,119 | 510,395 | 387,247 | |||||||||||
| Operating loss | (151,828 | ) | (87,548 | ) | (473,113 | ) | (334,467 | ) | |||||||
| Loss on extinguishment of debt(6) | — | — | — | (2,033 | ) | ||||||||||
| Gain on debt restructuring(7) | 154,407 | — | 154,407 | — | |||||||||||
| Interest expense | (2,757 | ) | (3,571 | ) | (13,412 | ) | (14,343 | ) | |||||||
| Other income, net | 4,065 | 8,383 | 23,783 | 32,684 | |||||||||||
| Income (loss) before income taxes | 3,887 | (82,736 | ) | (308,335 | ) | (318,159 | ) | ||||||||
| Income tax provision (benefit)(8) | 316 | (718 | ) | 316 | (11,424 | ) | |||||||||
| Net income (loss) | 3,571 | (82,018 | ) | (308,651 | ) | (306,735 | ) | ||||||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | 0.01 | $ | (0.31 | ) | $ | (1.12 | ) | $ | (1.21 | ) | ||||
| Diluted | $ | (0.49 | ) | $ | (0.31 | ) | $ | (1.58 | ) | $ | (1.21 | ) | |||
| Weighted average shares outstanding used in calculating net income (loss) per share | |||||||||||||||
| Basic | 282,999 | 267,121 | 274,488 | 253,629 | |||||||||||
| Diluted | 306,892 | 267,121 | 288,366 | 253,629 | |||||||||||
| (1) | Balance for the twelve months ended December 31, 2024 includes restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. |
| (2) | Balances for the three and twelve months ended December 31, 2024 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts. |
| (3) | Preliminary estimated goodwill and in-process research and development impairment charges during the three and twelve months ended December 31, 2024 of |
| (4) | Merger-related expenses for the three months ended December 31, 2023 consisted of transaction costs arising from the acquisition of Apton. Merger-related expenses for the twelve months ended December 31, 2023 consisted of |
| (5) | Change in fair value of contingent consideration during the three and twelve months ended December 31, 2024 and December 31, 2023 was due to fair value adjustments of milestone payments payable upon the achievement of the respective milestone event. |
| (6) | Loss on extinguishment of debt during the twelve months ended December 31, 2023 is related to the exchange of a portion of PacBio's |
| (7) | Gain on debt restructuring during the three and twelve months ended December 31, 2024, represents the gain resulting from the November 2024 convertible notes exchange transaction. |
| (8) | Deferred income tax benefits during the three and twelve months ended December 31, 2023 are related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. |
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Balance Sheets | ||||||
| (in thousands) | December 31, 2024 | December 31, 2023 | ||||
| Assets | ||||||
| Cash and investments | $ | 389,931 | $ | 631,416 | ||
| Accounts receivable, net | 27,524 | 36,615 | ||||
| Inventory, net | 58,755 | 56,676 | ||||
| Prepaid and other current assets | 18,781 | 17,040 | ||||
| Property and equipment, net | 30,505 | 36,432 | ||||
| Operating lease right-of-use assets, net | 16,091 | 32,593 | ||||
| Restricted cash | 2,222 | 2,722 | ||||
| Intangible assets, net (1) | 394,572 | 456,984 | ||||
| Goodwill (2) | 313,961 | 462,261 | ||||
| Other long-term assets | 9,305 | 13,274 | ||||
| Total Assets | $ | 1,261,647 | $ | 1,746,013 | ||
| Liabilities and Stockholders' Equity | ||||||
| Accounts payable | $ | 16,590 | $ | 15,062 | ||
| Accrued expenses | 22,595 | 45,708 | ||||
| Deferred revenue | 19,764 | 21,872 | ||||
| Operating lease liabilities | 24,940 | 41,197 | ||||
| Contingent consideration liability | 18,700 | 19,550 | ||||
| Convertible senior notes, net | 647,494 | 892,243 | ||||
| Other liabilities | 3,770 | 9,077 | ||||
| Stockholders' equity | 507,794 | 701,304 | ||||
| Total Liabilities and Stockholders' Equity | $ | 1,261,647 | $ | 1,746,013 | ||
| (1) | Balance as of December 31, 2024 reflects preliminary estimated in-process research and development impairment charge of |
| (2) | Balance as of December 31, 2024 reflects preliminary estimated goodwill impairment charge of |
| Pacific Biosciences of California, Inc. Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||
| (in thousands, except per share amounts) | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | |||||||||||||||
| GAAP net income (loss) | $ | 3,571 | $ | (60,725 | ) | $ | (82,018 | ) | $ | (308,651 | ) | $ | (306,735 | ) | ||||||
| Impairment charges (1) | 90,100 | — | — | 183,300 | — | |||||||||||||||
| Merger-related expenses (2) | — | — | 63 | — | 9,042 | |||||||||||||||
| Change in fair value of contingent consideration (3) | (1,950 | ) | 1,170 | 1,100 | (850 | ) | 15,060 | |||||||||||||
| Loss on extinguishment of debt (4) | — | — | — | — | 2,033 | |||||||||||||||
| Gain on debt restructuring (5) | (154,407 | ) | — | — | (154,407 | ) | — | |||||||||||||
| Amortization of acquired intangible assets | 6,850 | 6,850 | 6,849 | 27,399 | 8,244 | |||||||||||||||
| Income tax benefit (6) | — | — | (718 | ) | — | (11,424 | ) | |||||||||||||
| Restructuring (7) | 493 | 6,701 | 2,224 | 25,222 | 2,224 | |||||||||||||||
| Non-GAAP net loss | $ | (55,343 | ) | $ | (46,004 | ) | $ | (72,500 | ) | $ | (227,987 | ) | $ | (281,556 | ) | |||||
| GAAP basic net income (loss) per share | $ | 0.01 | $ | (0.22 | ) | $ | (0.31 | ) | $ | (1.12 | ) | $ | (1.21 | ) | ||||||
| Impairment charges (1) | 0.32 | — | — | 0.67 | — | |||||||||||||||
| Merger-related expenses (2) | — | — | — | — | 0.04 | |||||||||||||||
| Change in fair value of contingent consideration (3) | (0.01 | ) | — | — | — | 0.06 | ||||||||||||||
| Loss on extinguishment of debt (4) | — | — | — | — | 0.01 | |||||||||||||||
| Gain on debt restructuring (5) | (0.55 | ) | — | — | (0.56 | ) | — | |||||||||||||
| Amortization of acquired intangible assets | 0.02 | 0.03 | 0.03 | 0.10 | 0.03 | |||||||||||||||
| Income tax benefit (6) | — | — | — | — | (0.05 | ) | ||||||||||||||
| Restructuring (7) | — | 0.02 | 0.01 | 0.09 | 0.01 | |||||||||||||||
| Other adjustments and rounding differences | 0.01 | — | — | (0.01 | ) | — | ||||||||||||||
| Non-GAAP basic net loss per share | $ | (0.20 | ) | $ | (0.17 | ) | $ | (0.27 | ) | $ | (0.83 | ) | $ | (1.11 | ) | |||||
| GAAP gross profit | $ | 10,058 | $ | 10,004 | $ | 9,571 | $ | 37,282 | $ | 52,780 | ||||||||||
| Amortization of acquired intangible assets | 2,221 | 3,201 | 1,433 | 9,393 | 1,983 | |||||||||||||||
| Restructuring (7) | — | (207 | ) | 112 | 4,443 | 112 | ||||||||||||||
| Non-GAAP gross profit | $ | 12,279 | $ | 12,998 | $ | 11,116 | $ | 51,118 | $ | 54,875 | ||||||||||
| GAAP gross profit % | 26 | % | 25 | % | 16 | % | 24 | % | 26 | % | ||||||||||
| Non-GAAP gross profit % | 31 | % | 33 | % | 19 | % | 33 | % | 27 | % | ||||||||||
| GAAP total operating expense | $ | 161,886 | $ | 74,081 | $ | 97,119 | $ | 510,395 | $ | 387,247 | ||||||||||
| Impairment charges (1) | (90,100 | ) | — | — | (183,300 | ) | — | |||||||||||||
| Merger-related expenses (2) | — | — | (63 | ) | — | (9,042 | ) | |||||||||||||
| Change in fair value of contingent consideration (3) | 1,950 | (1,170 | ) | (1,100 | ) | 850 | (15,060 | ) | ||||||||||||
| Amortization of acquired intangible assets | (4,629 | ) | (3,649 | ) | (5,416 | ) | (18,006 | ) | (6,261 | ) | ||||||||||
| Restructuring (7) | (493 | ) | (6,908 | ) | (2,112 | ) | (20,779 | ) | (2,112 | ) | ||||||||||
| Non-GAAP total operating expense | $ | 68,614 | $ | 62,354 | $ | 88,428 | $ | 289,160 | $ | 354,772 | ||||||||||
| (1) | Preliminary estimated goodwill and in-process research and development impairment charges during the three and twelve months ended December 31, 2024 of |
| (2) | Merger-related expenses for the three months ended December 31, 2023 consisted of transaction costs arising from the acquisition of Apton. Merger-related expenses for the twelve months ended December 31, 2023 consisted of |
| (3) | Change in fair value of contingent consideration was due to fair value adjustments of milestone payments payable upon the achievement of the respective milestone event. |
| (4) | Loss on extinguishment of debt is related to the exchange of a portion of PacBio's |
| (5) | Gain on debt restructuring during the three and twelve months ended December 31, 2024, represents the gain resulting from the November 2024 convertible notes exchange transaction. |
| (6) | Deferred income tax benefits during the three and twelve months ended December 31, 2023 are related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. |
| (7) | Restructuring costs consist primarily of employee separation costs, accelerated amortization and depreciation for right-of-use assets, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office, including charges for excess inventory due to a decrease in internal demand relating to the expense reduction initiatives. |
FAQ
What caused PACB's 33% revenue decline in Q4 2024?
How many Revio and Vega systems did PACB sell in Q4 2024?
What is the impact of PACB's debt restructuring in Q4 2024?
What are the key features of PACB's new SPRQ chemistry?
How much cash does PACB have as of December 31, 2024?
